Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study is a prospective, randomized, open-label, multi-center trial. The primary objective of the study is to assess whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels at 24 weeks of treatment in dyslipidemia patients with prediabetes
Epistemonikos ID: 9fbffe8d2f73237ad8fa97b5dff80656a238954e
First added on: May 10, 2024